Does Kevzara Lower White Blood Cell Counts?
Yes, Kevzara (sarilumab) can lower white blood cell (WBC) counts, particularly neutrophils, a key type of WBC. This occurs because Kevzara is an IL-6 receptor blocker that suppresses immune activity, which may reduce neutrophil production or increase their destruction.[1][2] Clinical trials showed neutropenia (low neutrophils) in up to 10-20% of rheumatoid arthritis patients on Kevzara, with rates higher at 200 mg doses than 150 mg.[3]
How Common Is This Side Effect?
Neutropenia affects 6-16% of patients depending on dose and study duration. Severe cases (absolute neutrophil count below 500 cells/mm³) occur in about 1-2%.[1][3] WBC reductions often appear within weeks of starting treatment and may stabilize or resolve with monitoring or dose adjustments. Regular blood tests are required before and during therapy to track counts.[2]
What Happens If My WBC Count Drops?
Mild drops usually cause no symptoms, but severe neutropenia raises infection risk, including serious ones like pneumonia. Doctors monitor via complete blood counts (CBC) every 4-8 weeks initially, then less often if stable. If neutrophils fall below 1,000 cells/mm³, treatment may pause or adjust; below 500, it's often stopped temporarily.[1][2] Symptoms to watch include fever, chills, sore throat, or unusual fatigue—report these immediately.
Who Is at Higher Risk?
Patients with prior low WBC counts, infections, or using other immunosuppressants (e.g., methotrexate) face greater risk. Age over 65, higher doses, or concurrent infections also increase likelihood. Pre-treatment screening excludes those with active serious infections or very low baseline counts.[1][3]
How Do Doctors Manage Low WBC on Kevzara?
- Monitoring: Baseline CBC, then every 4 weeks for 3 months, every 3 months after.
- Dose changes: Reduce from 200 mg to 150 mg every 2 weeks if neutrophils are 500-1,000; hold if below 500 until recovery.
- Alternatives: If persistent, switch to other biologics like TNF inhibitors, which have different WBC profiles.[2]
No specific reversal drugs exist; counts typically recover 1-4 weeks after stopping.[3]
Comparison to Similar Drugs
Kevzara's neutropenia rate is similar to Actemra (tocilizumab, another IL-6 blocker) at 10-15%, but higher than TNF drugs like Humira (adalimumab, <5%). JAK inhibitors like Xeljanz (tofacitinib) also lower WBC but via different mechanisms, with comparable monitoring needs.[3]
[1]: Kevzara Prescribing Information (FDA)
[2]: Kevzara HCP Site (Sanofi/Regeneron)
[3]: Kevzara Clinical Trial Data (NEJM, Lancet)